Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Submit your nominations for the Fierce Innovation Awards - Entries close this Friday
anti-sense oligo
Biotech
Novartis Lp(a) drug fails closely watched ph. 3 trial
Lp(a) is a known cardiovascular risk factor, but lowering it in the 8,323-patient trial didn't reduce the risk of heart attacks and strokes.
Darren Incorvaia
Sep 4, 2026 9:18pm
GSK hep B drug cures one-fifth of patients in ‘major step’
May 28, 2026 4:30am
The 'diabolical' molecule set to become biotech's next gold rush
Apr 9, 2026 8:00am
FDA illuminates new approval pathway for bespoke gene therapies
Feb 23, 2026 11:30am
GSK's 'functional cure' for hep B proves worth in ph. 3 trials
Jan 7, 2026 6:15am
GSK pays $17.5M for CAMP4 regulatory RNA deal
Dec 18, 2025 7:00am
